View Older Stories View More Recent Stories

Mar 1, 2022 12:24PM William Blair Reiterates Albireo Pharma (ALBO) at Outperform, Bylvay Can Become a Blockbuster in Several Indications

Mar 1, 2022 12:06PM Needham & Company Reiterates Hold Rating on Zynerba Pharmaceuticals (ZYNE), Phase 3 RECONNECT Trial Remains Main Potential Value Driver

Mar 1, 2022 10:35AM Cantor Fitzgerald Reiterates Amarin Corporation (AMRN) at Overweight, "Street is Underestimating Multi-billion Dollar Opportunity for Vascepa/Vazkepa"

Mar 1, 2022 10:21AM Stifel Reiterates Buy Rating on Cerevel Therapeutics (CERE), Epilepsy Data From REALIZE Ph2 Study Remains Important Catalyst

Mar 1, 2022 09:30AM Aurinia Pharmaceuticals (AUPH) PT Lowered to $33 at H.C. Wainwright

Mar 1, 2022 09:21AM Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Mar 1, 2022 09:20AM Dawson James Reiterates First Wave BioPharma (FWBI) at Neutral, Puts MS1819 Probability of Success at 10%, Sees no Synergies With the Acquired Niclosamide

Mar 1, 2022 08:25AM BMO Capital Reiterates Pfizer (PFE) at Outperform, CLOVER Trial is Not Core but Substantial Attenuation in Infection is Encouraging Despite Endpoint Miss

Mar 1, 2022 08:22AM Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy, Anticipates Uptick Following Earnings

Mar 1, 2022 06:58AM Cantor Fitzgerald Reiterates Johnson & Johnson (JNJ) at Overweight, Pharm Business is Underappreciated, Expect Upwards Earnings Revisions and Multiple Expansion

Mar 1, 2022 06:56AM Cantor Fitzgerald Reiterates Ardelyx (ARDX) at Overweight, Peak Sales Potential of Pipeline is Underappreciated

Mar 1, 2022 06:54AM Cantor Fitzgerald Reiterates Overweight Rating on Humanigen (HGEN), Expects Upward Earnings Revisions

Mar 1, 2022 06:52AM Needham & Company Reiterates Revance Therapeutic (RVNC) at Buy, Names Conviction List Pick, Sees Daxi BLA Resubmission as Positive

Mar 1, 2022 06:50AM Cowen Reiterates Outperform Rating on Intellia Therapeutics (NTLA)

Mar 1, 2022 06:49AM Truist Securities Reiterates Fate Therapeutics (FATE) at Buy, Highlights Multiple Upcoming Readouts and Current Price Level

Mar 1, 2022 06:47AM Mizuho Securities Reiterates Buy Rating on Fate Therapeutics (FATE), Analyst Sees Opportunity for Shares to Reprice

Mar 1, 2022 06:44AM Cowen Reiterates Outperform on Turning Point Therapeutics (TPTX), Focus Remains on the 1L Updates

Mar 1, 2022 06:41AM Stifel Reiterates Buy Rating on CTI BioPharma (CTIC), Expects Stock to Trade Up Substantially on Vonjo Approval

Mar 1, 2022 06:39AM Mirati Therapeutics (MRTX) PT Lowered to $130 at BMO Capital

Mar 1, 2022 06:36AM Needham & Company Reiterates Acadia Pharmaceuticals (ACAD) at Hold, FDA Decision on pimavanserin's ADP sNDA Remains a Wildcard

Mar 1, 2022 06:31AM Heron Therapeutics (HRTX) PT Lowered to $16 at Needham & Company on Financial Overhang Concerns

Mar 1, 2022 06:28AM Needham & Company Reiterates Buy Rating on Merus N.V. (MRUS), Focus Remains on Pipeline

Mar 1, 2022 06:27AM Mirati Therapeutics (MRTX) PT Lowered to $118 at Stifel on More Conservative NSCLC Estimates, Remain Bullish on Prospects of adagrasib

Mar 1, 2022 06:24AM Truist Securities Reiterates Regeneron Pharma (REGN) at Buy, NTLA-2001 is an Underappreciated Opportunity with Significant Upside

Mar 1, 2022 06:19AM Stifel Reiterates Acadia Pharmaceuticals (ACAD) at Hold, Key Question Remains Whether sNDA for pimavanserin Will be Approved in ADP

Feb 28, 2022 11:49AM Cowen Reiterates Outperform Rating on Evelo Biosciences (EVLO) on New EDP1815 Data

Feb 28, 2022 11:30AM Needham & Company Reiterates Hold Rating on Zogenix (ZGNX) Following Earnings

Feb 28, 2022 10:55AM Raymond James Reiterates Outperform Rating on Harmony Biosciences (HRMY), Sees Continued Growth and Multiple Opportunities for Additional Upside

Feb 28, 2022 10:49AM Cowen Reiterates Outperform Rating on Arvinas Inc. (ARVN)

Feb 28, 2022 10:02AM Stifel Reiterates Buy Rating on Beam Therapeutics Inc (BEAM), "Like BEAM's Modular Platform and The Growth it Can Bring"

Feb 28, 2022 09:46AM Stifel Downgrades Gemini Therapeutics (GMTX) to Hold, Slashes Price Target to $2, Cites Lower Probability of Success for GEM103 and Higher Overall Risks

Feb 28, 2022 09:33AM Krystal Biotech (KRYS) PT Lowered to $107 at H.C. Wainwright

Feb 28, 2022 08:17AM Needham & Company Reiterates Harmony Biosciences (HRMY) at Buy, Doesn't Expect Stock to Move on Earnings

Feb 28, 2022 06:21AM H.C. Wainwright Reiterates Buy Rating on Akero Therapeutics (AKRO), HARMONY Trial Results Remain Key Catalyst

Feb 28, 2022 06:16AM Oppenheimer Reiterates VBI Vaccines (VBIV) at Outperform, ACIP Recommendation Sets Stage for PreHevbrio Coverage

Feb 25, 2022 03:58PM Stifel Reiterates Hold Rating on Inogen (INGN) Following Earnings, Company is On Good Trajectory, but Questions About Sustainability of Growth and Profitability Remain

Feb 25, 2022 03:18PM Ionis Pharmaceuticals (IONS) PT Lowered to $31 at Stifel Following Earnings, Focus Remains on Key Readouts from Pipeline

Feb 25, 2022 02:08PM Cowen Reiterates Y-mAbs Therapeutics (YMAB) at Outperform, Both Danyelza and Rest of Pipeline Continue to Progress

Feb 25, 2022 01:52PM William Blair Reiterates Biohaven Pharmaceutical (BHVN) at Outperform, Nurtec ODT Will Eventually Become Blockbuster Franchise

Feb 25, 2022 11:37AM H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

Feb 25, 2022 11:26AM Needham & Company Reiterates Buy Rating on Cytokinetics (CYTK) on Q4 Results and Upcoming Catalysts

Feb 25, 2022 10:54AM Cowen Reiterates Outperform Rating on uniQure BV (QURE)

Feb 24, 2022 10:19AM Sage Therapeutics (SAGE) PT Slashed to $58 at Stifel on Caution Over zuranolone, Notes that Overall Data Package Should be Enough for Approval

Feb 24, 2022 09:20AM Cantor Fitzgerald Reiterates Aclaris Therapeutis (ACRS) at Overweight, "Still a Lot of Value to be Unlocked in ACRS's Pipeline"

Feb 24, 2022 07:39AM William Blair Reiterates BioMarin Pharmaceutical (BMRN) at Outperform, "The Company Has a Promising Growth Profile"

Feb 24, 2022 07:26AM Needham & Company Reiterates Buy Rating on Sage Therapeutics (SAGE), Analysts Expects no Impact on Stock From the Recent Earning Readout

Feb 24, 2022 07:18AM Oppenheimer Reiterates BioMarin Pharmaceutical (BMRN) at Perform, Seeks Better Conviction Around Upcoming Catalysts

Feb 24, 2022 06:20AM Cantor Fitzgerald Reiterates Overweight Rating on Vaxcyte (PCVX), VAX-24 Study Patient Dosing Brings the Company Closer to Potential Commercialization

Feb 24, 2022 06:18AM Truist Securities Reiterates Buy Rating on BioMarin Pharmaceutical (BMRN), Guidance Indicates Strong Demand for Voxzogo

Feb 24, 2022 06:16AM Stifel Reiterates NuVasive (NUVA) at Buy, Ongoing Product Launches Should Support Strong Growth Rate

View More Recent Stories View Older Stories